1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer

CONCERT's over: Pfizer and Medivation drop Alzheimer's candidate Dimebon

 
• By Eleanor Malone

Pfizer and Medivation have dropped all further development of Dimebon (latrepirdine) after it failed to reach the two primary endpoints in the Phase III CONCERT trial in Alzheimer's disease. There had once been high hopes for the candidate, but disappointing results from earlier studies in Alzheimer's and Huntington's disease meant that this result had been widely anticipated.

Pfizer and Medivation have dropped all further development of Dimebon (latrepirdine) after it failed to reach the two primary endpoints in the Phase III CONCERT trial in Alzheimer's disease. There had once been high hopes for the candidate, but disappointing results from earlier studies in Alzheimer's and Huntington's disease meant that this result had been widely anticipated.

The CONCERT trial examined the use of Dimebon when added to ongoing treatment with Pfizer/Eisai's AChE inhibitor Aricept (donepezil) in...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

Multiple Factors Driving Japan’s Pioneering Angiosarcoma Pipeline

 
• By Lisa Takagi

Japan has emerged as a global leader in the development of new drugs for the rare cancer angiosarcoma, reflecting its rapidly ageing population and the limitations of current therapies.

Prasad’s Exit From CBER Could Bode Well For Genetic Medicines

 
• By Jessica Merrill

Pharma companies like Sarepta, Replimune and Capricor made gains on Wall Street after news broke that the FDA Center for Biologics Evaluation and Research director Vinay Prasad is leaving.

Blenrep Questions Won’t Go Away But GSK Sees Chance To Lead In COPD

 
• By Andrew McConaghie

GSK is sticking to its guns on its forecasts for Blenrep and the firm’s total sales in 2031 despite concerns about the antibody-drug conjugate’s approvability in the US.

Lilly’s Jaypirca Threatens Imbruvica’s CLL Position After Phase III Results

 
• By Alaric DeArment

The BRUIN CLL-314 trial was designed to show noninferiority, but the p-value indicated a favorable result for Jaypirca in both the pre-treated and intent-to-treat populations.

More from Therapeutic Category

Biogen Edges Closer To Growth On Strong Q2

 
• By Jessica Merrill

Sales of Leqembi, Zurzuvae and Skyclarys contributed to Biogen’s sales and earnings guidance raise, positioning the company closer to potential growth.

Amvuttra Makes Strong ATTR-CM Showing As Alnylam Prepares For Global Launches

 
• By Alaric DeArment

In an interview, chief commercial officer Tolga Tanguler gave some ideas of what to expect as the company prepares to launch the drug for ATTR-CM in Europe.

Argenx Powers Ahead With Vyvgart’s Prefilled Syringe Launch

 
• By Andrew McConaghie

The Netherlands-headquartered company is enjoying huge success with Vyvgart in two autoimmune conditions, with a new prefilled syringe version reaching more patient groups.